Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2018

26.10.2017 | Original Article

Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

verfasst von: Han Soo Yoo, Seok Jong Chung, Su Jin Chung, Hyojeong Moon, Jung Su Oh, Jae Seung Kim, Jin Yong Hong, Byoung Seok Ye, Young Ho Sohn, Phil Hyu Lee

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Reduced presynaptic dopaminergic activity plays an important role in the development of levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD). In this study, we investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of LID onset.

Methods

From among 412 drug-naive PD patients who underwent a dopamine transporter (DAT) PET scan during their baseline evaluation, we enrolled 65 patients who developed LID during a follow-up period of >2 years. Based on the time from PD onset, LID was classified as early, intermediate or late onset. We then compared DAT availability in the striatal subregions of the patients in the three groups.

Results

The demographic characteristics did not differ among the three patient groups except for earlier intervention of levodopa therapy in the early LID onset group (p = 0.001). After adjusting for age at PD onset, gender, timing of levodopa therapy from PD onset, and the severity of PD motor symptoms, DAT activity in the posterior putamen was found to be significantly lower in the early LID onset group than in the late LID onset group (p = 0.017). Multivariate linear regression analysis showed that low DAT activity in the posterior putamen was significantly associated with the early appearance of LID in the early LID onset group (β = 16.039, p = 0.033).

Conclusion

This study demonstrated that low DAT activity in the posterior putamen at baseline is a major risk factor for the early onset of LID in patients with PD, suggesting that the degree of presynaptic dopaminergic denervation plays an important role in determining the timing of LID onset.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20(4):415–55.CrossRefPubMed Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20(4):415–55.CrossRefPubMed
2.
Zurück zum Zitat Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology. 1990;40(2):340–5.CrossRefPubMed Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology. 1990;40(2):340–5.CrossRefPubMed
3.
Zurück zum Zitat Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, et al. Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12(12):956–63.CrossRefPubMed Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, et al. Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12(12):956–63.CrossRefPubMed
4.
Zurück zum Zitat Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2(8):577–88.CrossRefPubMed Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2(8):577–88.CrossRefPubMed
5.
Zurück zum Zitat Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem. 2006;99(2):381–92.CrossRefPubMed Cenci MA, Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem. 2006;99(2):381–92.CrossRefPubMed
6.
Zurück zum Zitat Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord. 2008;23(Suppl 3):S570–9.CrossRefPubMed Calabresi P, Di Filippo M, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord. 2008;23(Suppl 3):S570–9.CrossRefPubMed
7.
Zurück zum Zitat Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav. 1989;34(1):193–6.CrossRefPubMed Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav. 1989;34(1):193–6.CrossRefPubMed
8.
Zurück zum Zitat Boyce S, Rupniak NM, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol. 1990;13(5):448–58.CrossRefPubMed Boyce S, Rupniak NM, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol. 1990;13(5):448–58.CrossRefPubMed
9.
Zurück zum Zitat de la Fuente-Fernandez R, Pal PK, Vingerhoets FJ, Kishore A, Schulzer M, Mak EK, et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm. 2000;107(1):49–57.CrossRefPubMed de la Fuente-Fernandez R, Pal PK, Vingerhoets FJ, Kishore A, Schulzer M, Mak EK, et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm. 2000;107(1):49–57.CrossRefPubMed
10.
Zurück zum Zitat Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 1998;50(5 Suppl 5):S17–25.CrossRefPubMed Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 1998;50(5 Suppl 5):S17–25.CrossRefPubMed
11.
Zurück zum Zitat Hong JY, Oh JS, Lee I, Sunwoo MK, Ham JH, Lee JE, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology. 2014;82(18):1597–604.CrossRefPubMed Hong JY, Oh JS, Lee I, Sunwoo MK, Ham JH, Lee JE, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology. 2014;82(18):1597–604.CrossRefPubMed
12.
Zurück zum Zitat Huot P. L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite? J Neurol Sci. 2015;351(1-2):9–12.CrossRefPubMed Huot P. L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite? J Neurol Sci. 2015;351(1-2):9–12.CrossRefPubMed
13.
Zurück zum Zitat Sunwoo MK, Kim KM, Hong JY, Sohn YH, Lee PH. Levodopa-induced dyskinesia in a patient who has normal presynaptic dopaminergic neurons. Mov Disord. 2013;28(8):1152–3.CrossRefPubMed Sunwoo MK, Kim KM, Hong JY, Sohn YH, Lee PH. Levodopa-induced dyskinesia in a patient who has normal presynaptic dopaminergic neurons. Mov Disord. 2013;28(8):1152–3.CrossRefPubMed
14.
Zurück zum Zitat Bedard PJ, Blanchet PJ, Levesque D, Soghomonian JJ, Grondin R, Morissette M, et al. Pathophysiology of L-dopa-induced dyskinesias. Mov Disord. 1999;14(Suppl 1):4–8.PubMed Bedard PJ, Blanchet PJ, Levesque D, Soghomonian JJ, Grondin R, Morissette M, et al. Pathophysiology of L-dopa-induced dyskinesias. Mov Disord. 1999;14(Suppl 1):4–8.PubMed
15.
Zurück zum Zitat Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–91.CrossRefPubMed Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–91.CrossRefPubMed
16.
Zurück zum Zitat Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52.CrossRefPubMedPubMedCentral Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord. 2008;23(13):1825–9.CrossRefPubMed Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord. 2008;23(13):1825–9.CrossRefPubMed
18.
Zurück zum Zitat Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012;53(3):399–406.CrossRefPubMed Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med. 2012;53(3):399–406.CrossRefPubMed
19.
Zurück zum Zitat Hong JY, Sunwoo MK, Oh JS, Kim JS, Sohn YH, Lee PH. Persistent drug-induced parkinsonism in patients with normal dopamine transporter imaging. PLoS One. 2016;11(6):e0157410.CrossRefPubMedPubMedCentral Hong JY, Sunwoo MK, Oh JS, Kim JS, Sohn YH, Lee PH. Persistent drug-induced parkinsonism in patients with normal dopamine transporter imaging. PLoS One. 2016;11(6):e0157410.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary parkinsonisms. Mov Disord. 2011;26(6):1083–95.CrossRefPubMed Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary parkinsonisms. Mov Disord. 2011;26(6):1083–95.CrossRefPubMed
21.
Zurück zum Zitat Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.CrossRefPubMed Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.CrossRefPubMed
22.
Zurück zum Zitat Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L. Akinetic-rigid and tremor-dominant Parkinson’s disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov Disord. 2011;26(3):416–23.CrossRefPubMed Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L. Akinetic-rigid and tremor-dominant Parkinson’s disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov Disord. 2011;26(3):416–23.CrossRefPubMed
23.
Zurück zum Zitat Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21(9):1034–57.CrossRefPubMed Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21(9):1034–57.CrossRefPubMed
24.
Zurück zum Zitat Oh JS, Oh M, Chung SJ, Kim JS. Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia. Neuroreport. 2014;25(15):1198–202.CrossRefPubMed Oh JS, Oh M, Chung SJ, Kim JS. Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia. Neuroreport. 2014;25(15):1198–202.CrossRefPubMed
25.
Zurück zum Zitat Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.CrossRefPubMed Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.CrossRefPubMed
26.
Zurück zum Zitat Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18(11):1250–6.CrossRefPubMed Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18(11):1250–6.CrossRefPubMed
27.
Zurück zum Zitat Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson’s disease. Clin Neuropharmacol. 1998;21(2):118–21.PubMed Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson’s disease. Clin Neuropharmacol. 1998;21(2):118–21.PubMed
28.
Zurück zum Zitat Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005;62(4):601–5.CrossRefPubMed Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005;62(4):601–5.CrossRefPubMed
29.
Zurück zum Zitat Parkinson study group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39(1):29–36.CrossRef Parkinson study group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39(1):29–36.CrossRef
30.
Zurück zum Zitat Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21(11):1844–50.CrossRefPubMed Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21(11):1844–50.CrossRefPubMed
31.
Zurück zum Zitat Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22(10):1379–89.CrossRefPubMed Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22(10):1379–89.CrossRefPubMed
32.
Zurück zum Zitat Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123:2297–305.CrossRefPubMed Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123:2297–305.CrossRefPubMed
33.
Zurück zum Zitat Denny AP, Behari M. Motor fluctuations in Parkinson’s disease. J Neurol Sci. 1999;165(1):18–23.CrossRefPubMed Denny AP, Behari M. Motor fluctuations in Parkinson’s disease. J Neurol Sci. 1999;165(1):18–23.CrossRefPubMed
34.
Zurück zum Zitat Yahalom G, Cohen OS, Warmann-Alaluf N, Shabat C, Strauss H, Elincx-Benizri S, et al. The impact of early versus late levodopa administration. J Neural Transm. 2017;124(4):471–6.CrossRefPubMed Yahalom G, Cohen OS, Warmann-Alaluf N, Shabat C, Strauss H, Elincx-Benizri S, et al. The impact of early versus late levodopa administration. J Neural Transm. 2017;124(4):471–6.CrossRefPubMed
35.
Zurück zum Zitat Nadjar A, Gerfen CR, Bezard E. Priming for L-dopa-induced dyskinesia in Parkinson’s disease: a feature inherent to the treatment or the disease? Prog Neurobiol. 2009;87(1):1–9.CrossRefPubMed Nadjar A, Gerfen CR, Bezard E. Priming for L-dopa-induced dyskinesia in Parkinson’s disease: a feature inherent to the treatment or the disease? Prog Neurobiol. 2009;87(1):1–9.CrossRefPubMed
36.
Zurück zum Zitat Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson’s disease. J Neural Transm. 2005;112(3):359–91.CrossRefPubMed Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson’s disease. J Neural Transm. 2005;112(3):359–91.CrossRefPubMed
37.
Zurück zum Zitat Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol. 2000;47(4 Suppl 1):S90–9.PubMed Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol. 2000;47(4 Suppl 1):S90–9.PubMed
38.
Zurück zum Zitat Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2004;16(1):110–23.CrossRefPubMed Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2004;16(1):110–23.CrossRefPubMed
39.
Zurück zum Zitat Scholz B, Svensson M, Alm H, Skold K, Falth M, Kultima K, et al. Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. PLoS One. 2008;3(2):e1589.CrossRefPubMedPubMedCentral Scholz B, Svensson M, Alm H, Skold K, Falth M, Kultima K, et al. Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. PLoS One. 2008;3(2):e1589.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Winkler C, Kirik D, Bjorklund A, Cenci MA. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2002;10(2):165–86.CrossRefPubMed Winkler C, Kirik D, Bjorklund A, Cenci MA. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2002;10(2):165–86.CrossRefPubMed
41.
Zurück zum Zitat Iravani MM, McCreary AC, Jenner P. Striatal plasticity in Parkinson’s disease and L-dopa induced dyskinesia. Parkinsonism Relat Disord. 2012;18(Suppl 1):S123–5.CrossRefPubMed Iravani MM, McCreary AC, Jenner P. Striatal plasticity in Parkinson’s disease and L-dopa induced dyskinesia. Parkinsonism Relat Disord. 2012;18(Suppl 1):S123–5.CrossRefPubMed
42.
Zurück zum Zitat Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson’s disease: epidemiology, etiology, and treatment. Curr Neurol Neurosci Rep. 2007;7(4):302–10.CrossRefPubMed Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson’s disease: epidemiology, etiology, and treatment. Curr Neurol Neurosci Rep. 2007;7(4):302–10.CrossRefPubMed
43.
Zurück zum Zitat Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord. 1987;2(2):73–91.CrossRefPubMed Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord. 1987;2(2):73–91.CrossRefPubMed
44.
Zurück zum Zitat Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756–60.CrossRefPubMed Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756–60.CrossRefPubMed
45.
Zurück zum Zitat Onofrj M, Paci C, Thomas A. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;65(4):605–6.CrossRefPubMedPubMedCentral Onofrj M, Paci C, Thomas A. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1998;65(4):605–6.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, Part II. Ann Neurol. 1988;24(3):372–8.CrossRefPubMed Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, Part II. Ann Neurol. 1988;24(3):372–8.CrossRefPubMed
47.
Zurück zum Zitat Cenci MA. Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol. 2014;5:242.CrossRefPubMedPubMedCentral Cenci MA. Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol. 2014;5:242.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord. 2000;15(3):459–66.CrossRefPubMed Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord. 2000;15(3):459–66.CrossRefPubMed
49.
Zurück zum Zitat Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):378–82.CrossRefPubMed Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):378–82.CrossRefPubMed
50.
Zurück zum Zitat Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease shows nonlinear progression in the putamen. Mov Disord. 2009;24(7):1009–15.CrossRefPubMed Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease shows nonlinear progression in the putamen. Mov Disord. 2009;24(7):1009–15.CrossRefPubMed
51.
Zurück zum Zitat Kuriakose R, Stoessl AJ. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Prog Brain Res. 2010;184:177–92.CrossRefPubMed Kuriakose R, Stoessl AJ. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. Prog Brain Res. 2010;184:177–92.CrossRefPubMed
52.
Zurück zum Zitat Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37(4):554–9.PubMed Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37(4):554–9.PubMed
53.
Zurück zum Zitat Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppanen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson’s disease. Neurobiol Aging. 2015;36(4):1757–63.CrossRefPubMed Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppanen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson’s disease. Neurobiol Aging. 2015;36(4):1757–63.CrossRefPubMed
54.
Zurück zum Zitat Lee JJ, Oh JS, Ham JH, Lee DH, Lee I, Sohn YH, et al. Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson’s disease. Neurobiol Aging. 2016;38:197–204.CrossRefPubMed Lee JJ, Oh JS, Ham JH, Lee DH, Lee I, Sohn YH, et al. Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson’s disease. Neurobiol Aging. 2016;38:197–204.CrossRefPubMed
55.
Zurück zum Zitat Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 2005;1046(1-2):230–3.CrossRefPubMed Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 2005;1046(1-2):230–3.CrossRefPubMed
56.
Zurück zum Zitat Ballanger B, Beaudoin-Gobert M, Neumane S, Epinat J, Metereau E, Duperrier S, et al. Imaging dopamine and serotonin systems on MPTP monkeys: a longitudinal PET investigation of compensatory mechanisms. J Neurosci. 2016;36(5):1577–89.CrossRefPubMed Ballanger B, Beaudoin-Gobert M, Neumane S, Epinat J, Metereau E, Duperrier S, et al. Imaging dopamine and serotonin systems on MPTP monkeys: a longitudinal PET investigation of compensatory mechanisms. J Neurosci. 2016;36(5):1577–89.CrossRefPubMed
57.
Zurück zum Zitat Nevalainen N, Af Bjerken S, Gerhardt GA, Stromberg I. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia. Neuroscience. 2014;260:73–86.CrossRefPubMed Nevalainen N, Af Bjerken S, Gerhardt GA, Stromberg I. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia. Neuroscience. 2014;260:73–86.CrossRefPubMed
58.
Zurück zum Zitat Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse. 1997;25(4):345–9.CrossRefPubMed Scheffel U, Lever JR, Abraham P, Parham KR, Mathews WB, Kopajtic T, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse. 1997;25(4):345–9.CrossRefPubMed
Metadaten
Titel
Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease
verfasst von
Han Soo Yoo
Seok Jong Chung
Su Jin Chung
Hyojeong Moon
Jung Su Oh
Jae Seung Kim
Jin Yong Hong
Byoung Seok Ye
Young Ho Sohn
Phil Hyu Lee
Publikationsdatum
26.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3844-8

Weitere Artikel der Ausgabe 3/2018

European Journal of Nuclear Medicine and Molecular Imaging 3/2018 Zur Ausgabe